Format

Send to

Choose Destination
Mol Cancer Ther. 2010 Nov;9(11):3065-73. doi: 10.1158/1535-7163.MCT-10-0623. Epub 2010 Sep 3.

Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.

Author information

1
University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue MSB-E650, Newark, NJ 07103, USA. tuncerah@umdnj.edu

Abstract

Despite the initial effectiveness of oncogene-directed cancer therapeutics, acquired drug resistance remains the ultimate "Achilles' heel" for long-term durable remission in cancer patients. Acquisition of drug resistance is not more evident elsewhere than in the use of tyrosine kinase inhibitors, imatinib and dasatinib, for patients with chronic myelogenous leukemia. Hence, even though imatinib initially produces remission in the chronic phase, ultimately these therapeutics fail via the emergence of drug resistance, in which chronic myelogenous leukemia could inevitably progress to a terminal blast phase culminating in fatal outcome. Technically, it is challenging to predict the onset of drug resistance in a small number of oncogene-transformed cells, making the decision of when and how to employ second-generation tyrosine kinase inhibitors, or employ novel compounds that would be of benefit in treating drug-resistant Bcr-Abl mutants mainly retrospective. Here, we characterize a rapid and sensitive real-time fluorescent resonance energy transfer-based assay that is able to detect the in vivo activity of Bcr-Abl and its inhibition by small molecule compounds. Due to its real-time and in vivo nature, such an approach has the potential to monitor a drug-resistant phenotype, as well as to identify pharmaceutical agents that inhibit drug-resistant Bcr-Abl oncoproteins in vivo.

PMID:
20817824
PMCID:
PMC3318989
DOI:
10.1158/1535-7163.MCT-10-0623
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center